Investor Presentaiton

Investor Presentation First six months of 2018 Slide 96 Novo Nordisk maintains leadership within growth disorder Development in global growth disorder market DKK billion 20 15 10 5 0 May 2013 - MAT volume kg CAGR volume¹: 14.5% CAGR value DKK¹: 18.8% 1 CAGR for 5-year period Source: IQVIA monthly MAT May, 2018 volume figures and value (DKK) figures changing diabetes® Growth disorder volume market share MAT value DKK kg 120 35% 100 30% 25% 80 20% +60 15% 40 10% 20 5% 0 0% May 2018 May 2013 Novo Nordisk Eli Lilly Source: IQVIA monthly MAT May, 2018 volume figures Pfizer Merck Kgaa Sandoz 27% May 2018 novo nordisk

View entire presentation